Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MNKD | PRESS-RELEASE | bullish | 8/10 | MannKind announced FDA approval of Afrezza (inhaled insulin) for pediatric patients aged 6+ with type 1 and type 2 diabe | May 29, 2026 |
| REPL | 8-K | bullish | 7/10 | Replimune announced it will resubmit its Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in comb | May 29, 2026 |
| MBRX | 8-K | bullish | 6/10 | Moleculin Biotech presented a pooled analysis at ASCO 2026 showing no detectable cardiotoxicity for its lead drug Annamy | May 29, 2026 |
| TRAW | DEFA14A | neutral | 3/10 | Traws Pharma filed DEFA14A additional definitive proxy soliciting materials for its 2026 Annual Meeting scheduled for Ju | May 29, 2026 |
| CLRB | S-1/A | bearish | 6/10 | Cellectar Biosciences filed Amendment No. 1 to its S-1 registration statement to register up to 51,998,413 shares of com | May 29, 2026 |
| HIND | 8-K | bearish | 5/10 | Vyome Holdings reported Q1 2026 EPS of -$0.15, beating the consensus estimate of -$0.19 by 21%, but revenue collapsed 84 | May 29, 2026 |
| CMND | 6-K | neutral | 3/10 | Clearmind Medicine announced the publication of a Japanese patent application for its MEAI-based depression treatment, e | May 29, 2026 |
| CMND | PRESS-RELEASE | neutral | 3/10 | Clearmind Medicine announced a Japanese patent application for its MEAI-based depression treatment, expanding its IP por | May 29, 2026 |
| OPTH | PRESS-RELEASE | bullish | 6/10 | Optimi Health acknowledged the TGA's final recommendations expanding Australia's Authorized Prescriber scheme for psiloc | May 29, 2026 |
| OTLK | 424B5 | bearish | 7/10 | Outlook Therapeutics is issuing 8,539,709 shares of common stock at $0.5855 per share to a single accredited investor, r | May 29, 2026 |
| REPL | PRESS-RELEASE | bullish | 8/10 | Replimune announced alignment with the FDA on a path forward for resubmission of the RP1 BLA for advanced melanoma, with | May 29, 2026 |
| TPST | PRESS-RELEASE | bearish | 6/10 | Tempest Therapeutics announced a warrant exercise agreement to immediately raise ~$2M in gross proceeds by reducing the | May 29, 2026 |
| SABS | PRESS-RELEASE | neutral | 3/10 | SAB Biotherapeutics announced upcoming data presentations at the ADA and FOCIS conferences in June 2026, highlighting it | May 29, 2026 |
| SPRC | 6-K | neutral | 4/10 | SciSparc's subsidiary NeuroThera Labs received conditional TSX Venture Exchange approval for its acquisition of ~54% of | May 29, 2026 |
| APTOF | 8-K | neutral | 5/10 | Aptose Biosciences announced a further delay in closing its arrangement with Hanmi Pharmaceutical, now targeting June 20 | May 29, 2026 |
| AGIO | PRESS-RELEASE | bearish | 6/10 | Agios Pharmaceuticals announced it will not advance tebapivat, its next-generation oral PK activator, in lower-risk myel | May 29, 2026 |
| SLXNW | 8-K | neutral | 4/10 | Silexion Therapeutics Corp effected a 1-for-10 reverse share split of its ordinary shares, effective May 28, 2026, to ma | May 29, 2026 |
| PHVS | PRESS-RELEASE | neutral | 4/10 | Pharvaris announced the acceptance of 8 abstracts (1 oral, 7 flash talk/poster) at the EAACI 2026 congress, including Ph | May 29, 2026 |
| AZN | 6-K | bullish | 7/10 | AstraZeneca announced FDA approval of Imfinzi (durvalumab) in combination with BCG for BCG-naïve, high-risk non-muscle-i | May 29, 2026 |
| PRNAF | 6-K | neutral | 3/10 | Alterity Therapeutics filed a 6-K reporting the results of its 2026 Extraordinary General Meeting, where shareholders pa | May 29, 2026 |
| EXOZ | 424B5 | bearish | 7/10 | EXOZ is conducting a dilutive underwritten public offering of common stock and warrants under its existing $50M shelf re | May 29, 2026 |
| EXEL | CLUSTER | neutral | 3/10 | Two EVPs at Exelixis sold a combined $3.79M in open-market sales over a one-week window. The sales total ~0.03% of the $ | May 28, 2026 |
| NBIX | CLUSTER | neutral | 4/10 | Two Neurocrine insiders sold a combined $38.43M in shares over the past week, with Director Kevin Gorman accounting for | May 28, 2026 |
| SNGX | 8-K | bearish | 5/10 | Soligenix filed an 8-K to increase the maximum aggregate offering amount under its existing at-the-market (ATM) equity f | May 28, 2026 |
| SNGX | 424B5 | bearish | 6/10 | Soligenix filed a 424B5 prospectus supplement to update the maximum dollar amount of common stock it can sell under its | May 28, 2026 |
| ANAB | 144 | neutral | 3/10 | Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on May 28, 2026, indicating intent to sell 10,264 shares of co | May 28, 2026 |
| OTLK | 8-K | bearish | 7/10 | Outlook Therapeutics entered into a securities purchase agreement for a registered direct offering of 8,539,709 shares a | May 28, 2026 |
| ALLO | DEFA14A | neutral | 3/10 | Allogene Therapeutics filed a DEFA14A supplementing its 2026 proxy statement to disclose the CEO transition from David C | May 28, 2026 |
| ALLO | 8-K | neutral | 3/10 | Allogene Therapeutics announced a CEO transition: David Chang, M.D., Ph.D., will step down as President and CEO effectiv | May 28, 2026 |
| AAPG | 6-K | neutral | 2/10 | Ascentage Pharma disclosed that its trustee purchased 50,000 existing shares on-market for HK$1,909,800 (HK$38.196/share | May 28, 2026 |